Hikal Ltd. News and Updates

Name: Latest research reports of Hikal Ltd. authored by BP Wealth and published by - Trendlyne research reports.
Item: Hikal Ltd.
Rating: 1
Author: BP Wealth

Keep track of all breaking news on Hikal Ltd. from all sources in a single place.

Load latest

Hikal Ltd.

27 Oct 2021

398.45

2.11%

Earnings Call for Q2FY22 of Hikal Ltd

Conference Call with Hikal Management and Analysts on Q2FY22 Performance and Outlook. Listen to the full earnings transcript.

audio

Hikal Ltd.

26 Oct 2021

398.45

2.11%

Hikal Q2 results: PAT soars 63% YoY, but falls sequentially

livemint

Hikal Q2 result: Total revenue from operations increased 26% to 469 crore as compared to 371 crore in the year-ago period.

Hikal Ltd. has an average target of 420.00 from 1 broker.

Hikal Ltd.

15 Sep 2021

398.45

2.11%

Intraday stock for today: Experts give 'buy' tag despite 330% rise in 6 months

livemint

Intraday share for today: Hikal shares have given series of breakouts and looks highly bullish on the chart pattern, say experts

Hikal Ltd. is trading above all available SMAs

Hikal Ltd.

12 Aug 2021

398.45

2.11%

BP Equities Hikal Ltd Q1FY22 Result Update

Sell: Hikal Ltd.

Recommendation Target

BP Wealth

Hikal posted revenue of INR 4,568mn with 29.5% YoY growth which was slightly below our estimate of INR 4,627mn on account of lower production days due to the unavailability of oxygen for industrial use. On segmental performance: The crop protection segment grew by 31% (YoY) to INR 1,827mn on the back of Increased sales volume of existing as well as new products. Pharmaceutical segment revenue surged by 28% to INR 2,741mn based on increased volumes of existing API Generics and CDMO products. EBITDA margin improved by 607 bps to 21%, (was 277bps above our estimate) supported by a favourable product mix. EBIT margin of the Crop protection segment improved by 532bps (YoY) with 40% (vs 43.6% in Q1FY21) contribution to overall EBIT. The pharmaceutical...

Hikal Ltd. is trading above all available SMAs

Hikal Ltd.

09 Aug 2021

398.45

2.11%

Hold Hikal: target of Rs 590: ICICI Direct

Moneycontrol

ICICI Direct recommended hold rating on Hikal with a target price of Rs 590 in its research report dated August 07, 2021.

Hikal Ltd. has an average target of 420.00 from 1 broker.

Hikal Ltd.

05 Aug 2021

398.45

2.11%

Hikal Consolidated June 2021 Net Sales at Rs 456.78 crore, up 29.48% Y-o-Y

Moneycontrol

NULL

Hikal Ltd. has gained 30.00% in the last 1 Year

Hikal Ltd.

25 May 2021

398.45

2.11%

Buy Hikal; target of Rs 380: ICICI Direct

Moneycontrol

ICICI Direct is bullish on Hikal has recommended buy rating on the stock with a target price of Rs 380 in its research report dated May 8, 2021.

Hikal Ltd. has gained 30.00% in the last 1 Year

Hikal Ltd.

08 May 2021, 12:00AM

398.45

2.11%

BP Equities Hikal Ltd Q4FY21 Result Update

Hold: Hikal Ltd.

Recommendation Target

BP Wealth

Hikal posted revenue of INR 5,325mn with 40.5% YoY growth which was above our estimate of INR 4,859mn mainly driven by strong growth in the both Pharmaceutical and Crop protection segment. On segmental performance: The crop protection segment grew by 54% (YoY) to INR 2348mn on the back of strong volume growth in existing products and commercialization of a new product from their newly built facility in Panoli Pharmaceutical segment revenue surged by 32% to INR 2,977mn based on increased volumes of existing API Generics and CDMO products. During the quarter, the company has filled US DMF for Favipiravir API to supporting both domestic and global markets. Despite 129bps contraction in gross margin, EBITDA margin managed to improve by 188bps to 20.5%, was 142bps...

Hikal Ltd. has gained 30.00% in the last 1 Year

Hikal Ltd.

08 May 2021, 12:00AM

398.45

2.11%

BP Equities Hikal Ltd Q4FY21 Result Update

Hold: Hikal Ltd.

Recommendation Target

BP Wealth

Hikal Ltd. is trading above all available SMAs

Hikal Ltd.

08 May 2021, 12:00AM

398.45

2.11%

Hikal Ltd

Buy: Hikal Ltd.

Target

ICICI Securities Limited

The Q4 performance was above I-direct estimates across all fronts. Q4 margin performance was the highest in the past five years, showcasing Hikal's focus on high margin products and backward integration besides cost control measures. Going ahead, the management expects a margin improvement of 50-100 bps from this year onwards on the back of several cost rationalisation and efficiency improvement measures undertaken during the pandemic. Going by the capex guidance, (| 200 crore over the next 18 months) things are looking promising for FY22 onwards. Despite the...